What Is Retatrutide? The Next-Generation Weight Loss Medication

What Is Retatrutide?

Retatrutide is an investigational medication currently in Phase 3 clinical trials for obesity treatment. Developed by Eli Lilly (the same company that makes tirzepatide), retatrutide represents the next evolution in weight loss medications.

While semaglutide targets one hormone receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP), retatrutide goes further by targeting three: GLP-1, GIP, and glucagon receptors. This triple action is why researchers are calling it a "triple agonist" or "triagonist."

The addition of glucagon receptor activity is what makes retatrutide particularly interesting. Glucagon is a hormone that helps your body burn stored energy, including fat. By activating glucagon receptors, retatrutide may enhance fat burning beyond what current medications achieve.

Like the other medications in this class, retatrutide is given as a weekly injection. The medication is still under development, so the final dosing and formulations may differ from what's currently being tested.

The Triple Action Explained

To understand why retatrutide might be more effective than existing medications, let's look at what each receptor does:

GLP-1 (Glucagon-Like Peptide-1): This is the foundation of current weight loss medications. GLP-1 activation reduces appetite, slows stomach emptying, and helps regulate blood sugar. It's the receptor targeted by semaglutide and is also activated by tirzepatide.

GIP (Glucose-Dependent Insulinotropic Polypeptide): This hormone complements GLP-1's effects. It enhances the satiety signal and appears to improve how the body handles energy from food. Tirzepatide was the first medication to combine GLP-1 and GIP activity.

Glucagon: Here's where retatrutide adds something new. Glucagon is traditionally known as the hormone that raises blood sugar by releasing stored glucose from the liver. However, it also increases energy expenditure and may directly promote fat burning.

The concern with activating glucagon is that it could raise blood sugar too much. However, in retatrutide, the glucagon activity is balanced by the GLP-1 and GIP effects, which lower blood sugar. Early trials show the combination keeps blood sugar stable while potentially enhancing weight loss.

Think of it this way: GLP-1 and GIP reduce how much energy you take in (by reducing appetite), while glucagon increases how much energy you burn. Combining all three creates a more comprehensive approach to weight management.

Clinical Trial Results

The Phase 2 trial results for retatrutide were published in 2023 and caught the attention of medical researchers worldwide. Here's what the data showed:

In participants with obesity (average BMI around 37), after 48 weeks of treatment:

• The highest dose group (12mg) lost an average of 24.2% of body weight
• The 8mg group lost an average of 22.8% of body weight
• Lower doses still showed significant weight loss

To put this in perspective, a 24% weight loss for someone starting at 100kg means losing 24kg. This exceeds what's typically seen with tirzepatide and significantly exceeds semaglutide results.

Some participants lost even more weight. At 48 weeks, over 25% of participants in the highest dose group had lost more than 30% of their body weight. Weight loss was continuing at the end of the study, suggesting even greater losses might occur with longer treatment.

Beyond weight loss, the trial showed improvements in:

• Blood sugar control (in participants with and without diabetes)
• Blood pressure
• Cholesterol levels
• Liver fat content

The reduction in liver fat was particularly notable. Many participants had fatty liver disease, which improved significantly with treatment. This has implications beyond weight loss, as fatty liver is a growing health concern worldwide.

How It Compares to Other Medications

Let's compare the average weight loss results from clinical trials:

These numbers suggest a pattern: more receptor targets lead to more weight loss. However, it's important to note that the retatrutide numbers are from Phase 2 trials, while the others come from larger Phase 3 trials. Phase 3 results may differ somewhat.

For a detailed look at how current options compare, see our article on retatrutide versus tirzepatide.

Beyond raw weight loss numbers, retatrutide may offer other advantages:

• Greater improvements in fatty liver disease
• Potentially preserved muscle mass (the glucagon component may help)
• Robust metabolic improvements

However, it's still an investigational medication. We need Phase 3 trial results and real-world experience to fully understand its benefits and risks.

Potential Side Effects

In Phase 2 trials, retatrutide's side effect profile was similar to other GLP-1 medications. The most common issues were gastrointestinal:

• Nausea - particularly during dose increases
• Diarrhea - usually mild and temporary
• Vomiting - often related to eating too much or too fast
• Constipation
• Decreased appetite (this is partly how it works)

These side effects were dose-related, meaning higher doses tended to cause more issues. Most side effects were mild to moderate and improved over time. Gradual dose increases (like with other GLP-1 medications) help minimize these effects.

The addition of glucagon activity raised theoretical concerns about blood sugar increases or liver issues. However, in the trials, blood sugar actually improved, and no significant liver problems were observed. The glucagon effects appear to be balanced by the GLP-1 and GIP components.

As with other medications in this class, serious but rare side effects may include:

• Pancreatitis (inflammation of the pancreas)
• Gallbladder problems
• Allergic reactions

Phase 3 trials will provide more data on safety and side effects in larger, more diverse populations. For general guidance on managing common issues, see our article on managing nausea with GLP-1 medications.

Availability and Access

As of early 2026, retatrutide is not yet approved for general use. It's still undergoing Phase 3 clinical trials, which are the final stage before regulatory approval can be sought.

Expected timeline:

• Phase 3 trial results: Expected in late 2026 or 2027
• FDA submission: Likely 2027 if trials are successful
• Potential approval: 2027 or 2028
• Nigerian availability: Typically follows US/EU approval by months to years

For now, if you're interested in GLP-1 medications for weight loss, tirzepatide and semaglutide are the available options. Both have strong clinical evidence and are currently accessible in Nigeria through proper medical channels.

Some compounding pharmacies may claim to offer retatrutide, but without regulatory approval, such products cannot be verified for quality and safety. We recommend waiting for approved products or using currently approved medications.

For information on accessing current treatments, see our guide on how to get GLP-1 medications in Nigeria.